Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 17/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL351149 | 0.90 | UTS2R (0.43) | UTS2RKMT2ALMNAHTTSMN1; SMN2 | |
| SCHEMBL2231738 | 0.89 | UTS2R (0.42) | UTS2RKMT2A | |
| SCHEMBL639252 | 0.88 | LMNA (0.38) | UTS2RLMNAHTTSMN1; SMN2 | |
| SCHEMBL2230625 | 0.87 | UTS2R (0.40) | UTS2RLMNAHTTSMN1; SMN2 | |
| SCHEMBL2231120 | 0.87 | UTS2R (0.40) | UTS2RKMT2A | |
| SCHEMBL638666 | 0.85 | TP53 (0.46) | UTS2RKMT2ALMNAHTT | |
| SCHEMBL2230567 | 0.84 | UTS2R (0.40) | UTS2RKMT2A | |
| SCHEMBL636473 | 0.84 | UTS2R (0.40) | UTS2RKMT2ALMNAHTTSMN1; SMN2 | |
| SCHEMBL1884875 | 0.84 | SMN1; SMN2 (0.39) | UTS2RKMT2ALMNAHTTSMN1; SMN2 | |
| SCHEMBL2231327 | 0.83 | UTS2R (0.47) | UTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190657-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| EP-2354120-A1 | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof | XenoPort, Inc. (US) | 2011-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190657-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | APEH, ABAT, SI | UTS2R 1572/4885KMT2A 2442/4885LMNA 3875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.